ELDN vs. BLRX, CELU, RPHM, ANVS, IMMX, CALC, GANX, AEON, CKPT, and AADI
Should you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include BioLineRx (BLRX), Celularity (CELU), Reneo Pharmaceuticals (RPHM), Annovis Bio (ANVS), Immix Biopharma (IMMX), CalciMedica (CALC), Gain Therapeutics (GANX), AEON Biopharma (AEON), Checkpoint Therapeutics (CKPT), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical preparations" industry.
BioLineRx (NASDAQ:BLRX) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, community ranking, valuation and media sentiment.
BioLineRx's return on equity of -43.52% beat Eledon Pharmaceuticals' return on equity.
BioLineRx received 478 more outperform votes than Eledon Pharmaceuticals when rated by MarketBeat users. Likewise, 73.32% of users gave BioLineRx an outperform vote while only 71.43% of users gave Eledon Pharmaceuticals an outperform vote.
BioLineRx has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.
In the previous week, Eledon Pharmaceuticals had 23 more articles in the media than BioLineRx. MarketBeat recorded 27 mentions for Eledon Pharmaceuticals and 4 mentions for BioLineRx. Eledon Pharmaceuticals' average media sentiment score of 1.33 beat BioLineRx's score of 0.85 indicating that BioLineRx is being referred to more favorably in the media.
BioLineRx presently has a consensus target price of $21.00, indicating a potential upside of 3,120.86%. Eledon Pharmaceuticals has a consensus target price of $11.67, indicating a potential upside of 405.05%. Given Eledon Pharmaceuticals' higher possible upside, research analysts plainly believe BioLineRx is more favorable than Eledon Pharmaceuticals.
Eledon Pharmaceuticals has lower revenue, but higher earnings than BioLineRx. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.
1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by insiders. Comparatively, 19.4% of Eledon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
BioLineRx beats Eledon Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Eledon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eledon Pharmaceuticals Competitors List
Related Companies and Tools
